Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate

Min Sang Lee, Jung Eun Lee, Eunkyoung Byun, Nak Won Kim, Kyuri Lee, Haeshin Lee, Sang Jun Sim, Doo Sung Lee, Ji Hoon Jeong

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Low cytotoxicity and high cellular gene delivery capability are among the most important prerequisites for the selection of a non-viral carrier. Although calcium phosphate (CAP) nanoparticles have been long used for animal cell transfection, its rapid and uncontrollable crystal growth and lack of tissue specificity are among the most challenging problems that limit its use in the clinic. In this study, we report the development of CAP nanoparticles stabilized by a conjugate of the mussel-inspired adhesive molecule, 3,4-dihydroxy-l- phenylalanine (dopa), and a nontoxic hydrophilic natural polymer, hyaluronic acid (HA), for targeted siRNA delivery to tumors. CAP/siRNA/dopa-HA can form compact nanoparticles that effectively protect siRNA from enzymatic degradation despite the structural drawbacks of siRNA, such as low charge density and short and rigid structure. In addition, stabilized CAP nanoparticles were able to maintain their colloidal stability in a physiological salt condition for over a week. The superior ability of CAP/siRNA/dopa-HA to maintain the integrity of encapsulated siRNA and the stability in solution of the nanoparticles allow this formulation to achieve improved intratumoral accumulation of siRNA and a high level of target gene silencing in solid tumors after systemic administration. Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized calcium phosphate nanoparticle-based gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.

Original languageEnglish
Pages (from-to)122-130
Number of pages9
JournalJournal of Controlled Release
Volume192
DOIs
Publication statusPublished - 2014 Oct 28

Fingerprint

Hyaluronic Acid
Phenylalanine
Nanoparticles
Small Interfering RNA
Transfection
Neoplasms
Organ Specificity
calcium phosphate
Bivalvia
Gene Silencing
Crystallization
Adhesives
Genes
Polymers
Salts

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. / Lee, Min Sang; Lee, Jung Eun; Byun, Eunkyoung; Kim, Nak Won; Lee, Kyuri; Lee, Haeshin; Sim, Sang Jun; Lee, Doo Sung; Jeong, Ji Hoon.

In: Journal of Controlled Release, Vol. 192, 28.10.2014, p. 122-130.

Research output: Contribution to journalArticle

Lee, Min Sang ; Lee, Jung Eun ; Byun, Eunkyoung ; Kim, Nak Won ; Lee, Kyuri ; Lee, Haeshin ; Sim, Sang Jun ; Lee, Doo Sung ; Jeong, Ji Hoon. / Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. In: Journal of Controlled Release. 2014 ; Vol. 192. pp. 122-130.
@article{53fed49dea664455a1d1fddb09952637,
title = "Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate",
abstract = "Low cytotoxicity and high cellular gene delivery capability are among the most important prerequisites for the selection of a non-viral carrier. Although calcium phosphate (CAP) nanoparticles have been long used for animal cell transfection, its rapid and uncontrollable crystal growth and lack of tissue specificity are among the most challenging problems that limit its use in the clinic. In this study, we report the development of CAP nanoparticles stabilized by a conjugate of the mussel-inspired adhesive molecule, 3,4-dihydroxy-l- phenylalanine (dopa), and a nontoxic hydrophilic natural polymer, hyaluronic acid (HA), for targeted siRNA delivery to tumors. CAP/siRNA/dopa-HA can form compact nanoparticles that effectively protect siRNA from enzymatic degradation despite the structural drawbacks of siRNA, such as low charge density and short and rigid structure. In addition, stabilized CAP nanoparticles were able to maintain their colloidal stability in a physiological salt condition for over a week. The superior ability of CAP/siRNA/dopa-HA to maintain the integrity of encapsulated siRNA and the stability in solution of the nanoparticles allow this formulation to achieve improved intratumoral accumulation of siRNA and a high level of target gene silencing in solid tumors after systemic administration. Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized calcium phosphate nanoparticle-based gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.",
keywords = "3,4-Dihydroxy-l-phenylalanine, Calcium phosphate nanoparticle, Gene delivery, Hyaluronic acid, Targeted delivery",
author = "Lee, {Min Sang} and Lee, {Jung Eun} and Eunkyoung Byun and Kim, {Nak Won} and Kyuri Lee and Haeshin Lee and Sim, {Sang Jun} and Lee, {Doo Sung} and Jeong, {Ji Hoon}",
year = "2014",
month = "10",
day = "28",
doi = "10.1016/j.jconrel.2014.06.049",
language = "English",
volume = "192",
pages = "122--130",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate

AU - Lee, Min Sang

AU - Lee, Jung Eun

AU - Byun, Eunkyoung

AU - Kim, Nak Won

AU - Lee, Kyuri

AU - Lee, Haeshin

AU - Sim, Sang Jun

AU - Lee, Doo Sung

AU - Jeong, Ji Hoon

PY - 2014/10/28

Y1 - 2014/10/28

N2 - Low cytotoxicity and high cellular gene delivery capability are among the most important prerequisites for the selection of a non-viral carrier. Although calcium phosphate (CAP) nanoparticles have been long used for animal cell transfection, its rapid and uncontrollable crystal growth and lack of tissue specificity are among the most challenging problems that limit its use in the clinic. In this study, we report the development of CAP nanoparticles stabilized by a conjugate of the mussel-inspired adhesive molecule, 3,4-dihydroxy-l- phenylalanine (dopa), and a nontoxic hydrophilic natural polymer, hyaluronic acid (HA), for targeted siRNA delivery to tumors. CAP/siRNA/dopa-HA can form compact nanoparticles that effectively protect siRNA from enzymatic degradation despite the structural drawbacks of siRNA, such as low charge density and short and rigid structure. In addition, stabilized CAP nanoparticles were able to maintain their colloidal stability in a physiological salt condition for over a week. The superior ability of CAP/siRNA/dopa-HA to maintain the integrity of encapsulated siRNA and the stability in solution of the nanoparticles allow this formulation to achieve improved intratumoral accumulation of siRNA and a high level of target gene silencing in solid tumors after systemic administration. Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized calcium phosphate nanoparticle-based gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.

AB - Low cytotoxicity and high cellular gene delivery capability are among the most important prerequisites for the selection of a non-viral carrier. Although calcium phosphate (CAP) nanoparticles have been long used for animal cell transfection, its rapid and uncontrollable crystal growth and lack of tissue specificity are among the most challenging problems that limit its use in the clinic. In this study, we report the development of CAP nanoparticles stabilized by a conjugate of the mussel-inspired adhesive molecule, 3,4-dihydroxy-l- phenylalanine (dopa), and a nontoxic hydrophilic natural polymer, hyaluronic acid (HA), for targeted siRNA delivery to tumors. CAP/siRNA/dopa-HA can form compact nanoparticles that effectively protect siRNA from enzymatic degradation despite the structural drawbacks of siRNA, such as low charge density and short and rigid structure. In addition, stabilized CAP nanoparticles were able to maintain their colloidal stability in a physiological salt condition for over a week. The superior ability of CAP/siRNA/dopa-HA to maintain the integrity of encapsulated siRNA and the stability in solution of the nanoparticles allow this formulation to achieve improved intratumoral accumulation of siRNA and a high level of target gene silencing in solid tumors after systemic administration. Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized calcium phosphate nanoparticle-based gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.

KW - 3,4-Dihydroxy-l-phenylalanine

KW - Calcium phosphate nanoparticle

KW - Gene delivery

KW - Hyaluronic acid

KW - Targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=84905061755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905061755&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2014.06.049

DO - 10.1016/j.jconrel.2014.06.049

M3 - Article

C2 - 24995950

AN - SCOPUS:84905061755

VL - 192

SP - 122

EP - 130

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -